LISATA THERAP.INC.DL-001 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

LISATA THERAP.INC.DL-001 (8NE) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€17.74 Million

≈ $20.74 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how LISATA THERAP.INC.DL-001's Asset Resilience Ratio has changed over time. See LISATA THERAP.INC.DL-001 financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down LISATA THERAP.INC.DL-001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 8NE market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: LISATA THERAP.INC.DL-001 maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

LISATA THERAP.INC.DL-001 Industry Peers by Asset Resilience Ratio

Compare LISATA THERAP.INC.DL-001's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for LISATA THERAP.INC.DL-001 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for LISATA THERAP.INC.DL-001.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	€0.00 ≈ $0.00	€17.74 Million ≈ $20.74 Million	--
2024-12-31	42.96%	€15.04 Million ≈ $17.58 Million	€35.00 Million ≈ $40.92 Million	-8.13pp
2023-12-31	51.09%	€27.94 Million ≈ $32.67 Million	€54.69 Million ≈ $63.94 Million	+0.33pp
2022-12-31	50.76%	€37.07 Million ≈ $43.34 Million	€73.03 Million ≈ $85.38 Million	-21.73pp
2021-12-31	72.49%	€70.32 Million ≈ $82.21 Million	€97.01 Million ≈ $113.41 Million	--

pp = percentage points

About LISATA THERAP.INC.DL-001

F:8NE Germany Biotechnology

Market Cap

$7.83 Million

€6.69 Million EUR

Market Cap Rank

#27630 Global

#2381 in Germany

Share Price

€0.74

Change (1 day)

-5.16%

52-Week Range

€0.74 - €4.34

All Time High

€183.30